Company Quick10K Filing
NanoString Technologies
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 35 $934
10-Q 2019-11-05 Quarter: 2019-09-30
10-Q 2019-08-01 Quarter: 2019-06-30
10-Q 2019-05-10 Quarter: 2019-03-31
10-K 2019-03-11 Annual: 2018-12-31
10-Q 2018-11-08 Quarter: 2018-09-30
10-Q 2018-08-08 Quarter: 2018-06-30
10-Q 2018-05-09 Quarter: 2018-03-31
10-K 2018-03-07 Annual: 2017-12-31
10-Q 2017-11-08 Quarter: 2017-09-30
10-Q 2017-08-09 Quarter: 2017-06-30
10-Q 2017-05-05 Quarter: 2017-03-31
10-K 2017-03-09 Annual: 2016-12-31
10-Q 2016-11-04 Quarter: 2016-09-30
10-Q 2016-08-04 Quarter: 2016-06-30
10-Q 2016-05-06 Quarter: 2016-03-31
10-K 2016-03-11 Annual: 2015-12-31
10-Q 2015-11-03 Quarter: 2015-09-30
10-Q 2015-08-05 Quarter: 2015-06-30
10-Q 2015-05-11 Quarter: 2015-03-31
10-K 2015-03-13 Annual: 2014-12-31
10-Q 2014-11-10 Quarter: 2014-09-30
10-Q 2014-08-08 Quarter: 2014-06-30
10-Q 2014-05-15 Quarter: 2014-03-31
10-K 2014-03-27 Annual: 2013-12-31
10-Q 2013-11-08 Quarter: 2013-09-30
10-Q 2013-08-08 Quarter: 2013-06-30
8-K 2020-01-13 Sale of Shares, Other Events
8-K 2020-01-12 Earnings, Regulation FD, Exhibits
8-K 2019-12-03 Enter Agreement, M&A, Regulation FD, Exhibits
8-K 2019-11-04 Earnings, Exhibits
8-K 2019-10-30 Officers, Exhibits
8-K 2019-10-02 Officers
8-K 2019-07-31 Earnings, Exhibits
8-K 2019-06-18 Shareholder Vote
8-K 2019-05-09 Earnings, Exhibits
8-K 2019-05-07 Officers
8-K 2019-04-08 Officers
8-K 2019-03-25 Leave Agreement
8-K 2019-03-19 Other Events, Exhibits
8-K 2019-03-07 Earnings, Exhibits
8-K 2019-03-05 Officers
8-K 2019-01-06 Earnings, Regulation FD, Exhibits
8-K 2018-11-16 Enter Agreement, Off-BS Arrangement
8-K 2018-11-08 Earnings, Exhibits
8-K 2018-10-12 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-08-07 Earnings, Exhibits
8-K 2018-07-17 Other Events, Exhibits
8-K 2018-07-16 Earnings, Exhibits
8-K 2018-06-12 Shareholder Vote
8-K 2018-05-08 Earnings, Exhibits
8-K 2018-03-07 Earnings, Exhibits
8-K 2018-02-06 Officers, Regulation FD
8-K 2018-01-15 Officers, Exhibits
8-K 2018-01-05 Enter Agreement, Off-BS Arrangement, Earnings, Regulation FD, Exhibits

NanoString Technologies Financials

NSTG Metrics, Comps, Filings

Annual | Quarterly

Business

We develop, manufacture and sell products that unlock scientifically valuable and clinically actionable information from minute amounts of biological material. Our core technology is a unique, proprietary optical barcoding chemistry that enables the labeling and counting of single molecules. This proprietary chemistry may reduce the number of steps required to conduct certain types of scientific experiments and allow for multiple experiments to be conducted at once. As a result, we are able to develop tools that are easier for researchers to use and that may generate faster and more consistent scientific results.

We use our technology to develop tools for scientific research, primarily in the fields of genomics and proteomics, and also to develop clinical diagnostic tests. We currently have one commercially available product platform, our nCounter Analysis System instruments and related consumables. nCounter can be used to analyze the activity of up to 800 genes in a single experiment. nCounter is also used by clinicians to analyze gene activity relevant for diagnostic applications. Our proprietary nCounter-based Prosigna assay analyzes the activity of 50 genes to assess the risk of recurrence in breast cancer patients previously treated with radiation therapy. As of December 31, 2018, we had an installed base of approximately 730 nCounter systems, which our customers have used to publish more than 2,300 peer-reviewed scientific papers.

We have discovered other novel applications that utilize our proprietary barcoding chemistry, and we have two new product platforms under development. Following completion of product development, each of these new systems is expected to be commercialized as a new instrument along with associated consumables.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Coherus Biosciences (CHRS) 1,426,446 98% -14.3 -49% 240,456 244,441 120,531 117,705 -117,841 -101,504 1,448,146
Aerie Pharmaceuticals (AERI) 1,333,912 97% -5.3 -99% 234,141 78,383 48,445 46,777 -231,961 -232,051 1,224,549
Fate Therapeutics (FATE) 1,287,911 0% -16.9 -38% 199,877 72,351 8,136 0 -76,047 -72,754 1,231,249
Cellectis (CLLS) 1,259,324 0% 500,840 0 0 0 0 1,259,324
Momenta Pharmaceuticals (MNTA) 1,247,353 0% 55.6 0% 479,686 166,967 67,001 0 0 16,260 903,279
Sangamo Therapeutics (SGMO) 1,112,937 0% -9.3 -15% 673,481 227,733 76,018 0 -103,941 -101,206 940,215
Editas Medicine (EDIT) 1,098,569 0% -8.6 -29% 355,625 162,563 25,037 0 -103,327 -103,327 886,345
Rubius Therapeutics (RUBY) 1,097,865 -8.9 -27% 438,032 94,388 0 0 -116,812 -113,191 1,004,924
Orchard Therapeutics (ORTX) 1,076,754 0% 366,042 54,704 0 0 0 0 737,073
Voyager Therapeutics (VYGR) 976,608 0% -11.0 -15% 388,592 270,188 55,386 0 -58,837 -58,837 649,108
NanoString Technologies (NSTG) 934,392 62% -13.1 -34% 232,900 146,912 116,681 71,892 -79,532 -74,834 982,362
Atara Biotherapeutics (ATRA) 893,121 -3.1 -102% 274,144 41,865 0 0 -278,958 -272,494 832,568
Nightstar Therapeutics (NITE) 848,485 -30.4 -15% 169,733 20,013 0 0 -24,778 -24,842 754,265
Vericel (VCEL) 809,933 84% -44.2 -15% 125,826 37,284 79,992 67,351 -18,463 -17,997 795,971
MeiraGTx (MGTX) 715,870 0% -6.7 -30% 253,076 123,513 2,767 0 -75,286 -75,836 511,473
Adverum Biotechnologies (ADVM) 698,590 0% -9.1 -31% 209,884 32,144 903 0 -66,060 -65,833 599,783
Heska (HSKA) 668,781 45% 83.4 2% 162,844 39,592 122,676 55,221 2,588 7,898 658,789
Translate Bio (TBIO) 661,094 0% -4.8 -36% 302,549 186,852 4,068 0 -109,713 -107,221 514,194
Krystal Biotech (KRYS) 644,082 -31.0 -7% 205,156 6,866 0 0 -14,490 -14,490 448,582
Scholar Rock Holding (SRRK) 438,747 0% -6.8 -25% 196,911 67,956 8,145 0 -49,008 -47,974 324,744

Balance Sheet ($'000)2013-09-302013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash19,2929,94117,22321,85620,58326,1360
Accounts Receivable6,7928,33112,43619,72522,19319,56417,279
Inventory5,7166,7505,44410,13813,81220,05713,173
PP&E3,22311,8076,3669,41412,15814,05715,171
Assets71,29364,372102,74892,869126,373136,762147,558
Accounts Payable2,8743,3543,3803,2434,9354,0928,636
Long-Term Debt18,77918,80730,92641,77147,90248,93158,396
Liabilities31,40232,90357,93572,654114,06896,653110,689
Stockholders' Equity39,89131,46944,81320,21512,30540,10936,869
Income Statement ($'000)2013-09-302013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue31,40344,49756,63969,13472,010106,732
Cost of Revenue15,00921,14926,12630,24531,88036,331
Gross Profit16,39423,34830,51338,88940,13070,401
R&D14,97921,40424,59734,72046,88861,599
SG&A29,91251,06353,18662,70074,33478,195
Tax0069217204249
Net Income-29,281-50,038-45,581-47,089-43,562-77,400
Cash Flow ($'000)2013-09-302013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating-31,346-38,061-43,362-6,079-51,657-54,065
Cash Investing-32,955-24,27523,769-30,261-2,490-22,925
Cash Financing52,55069,56624,26835,09359,66875,081